Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
E. Jusufovic, M. Rijavec, D. Keser, P. Korosec, E. Sodja, E. Iljazovic, Z. Radojevic, M. Kosnik (Tuzla, Bosnia And Herzegovina; Golnik, Slovenia; Uzice, Republic Of Serbia). LSC 2012 abstract – Down-regulated let-7b and mir- 126 in tumors and surrounding tissue correlate with high microvessel density and poor survival outcomes in non-small-cell lung cancer patients. Eur Respir J 2012; 40: Suppl. 56, 4544

Member's Comments

No comment yet.

Related content which might interest you: A polymorphism, which exists intronic lesion of SLC5A10, affects DRG2 expression and survival outcome of early-stage non-small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Downregulated anti-angiogenic miR-19a, miR-126 and let-7b in non-small lung cancer have poor but different prognostic values in squamous and adenocarcinoma subtypes Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer Source: Eur Respir J 2013; 41: 1172-1178 Year: 2013 Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Does expression of betatubulin 3 correlate between primary non small cells lung cancer tumor and metastases? Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 EGFR and hTERT mRNA expression in non-small cell lung cancer patients – Diagnostic and prognostic implications Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 The risk of distant metastases and prognosis prediction in early stage squamous cell lung cancer (SqCLC) by means of 3 microRNAs expression assessment Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Microscopic vessel invasion and visceral pleural invasion are correlated with EMT, cancer stemness and resistance to therapy in lung adenocarcinoma Source: International Congress 2016 – Lung cancer immunology: latest research Year: 2016 High pretreatment plasma VEGF level is associated with shorter survival in paclitaxel-carboplatin treated non-small cell lung carcinoma patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Chemotherapy improves low performance status lung cancer patients Source: Eur Respir J 2007; 30: 1186-1192 Year: 2007